Saturday 17 October 2026
Export MGRX’s income statement to Excel — free account
Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.
0.30
0.02
−6.25%
Follow MGRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(2.14) | (1.58) | (32.80) | — | — |
P/S ratio |
16.34 | 7.78 | 6.39 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
2.42 | 1.97 | (86.95) | (15.40) | — |
P/Operating CF |
(6.91) | (4.24) | (2.75) | (66.48) | — |
P/B ratio |
0.49 | 0.34 | 6.03 | 70.38 | — |
Price to Tangible BV |
7.71 | 0.00 | 6.03 | 70.38 | — |
EV/Sales |
13.08 | 7.68 | 5.38 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(1.02) | (0.97) | (0.56) | (31.57) | — |
EV/FCF |
(1.03) | (0.99) | (0.56) | (31.57) | — |
Quick Ratio |
1.67 | 0.04 | 3.50 | 2.62 | 0.58 |
Current Ratio |
1.74 | 0.05 | 3.96 | 2.67 | 0.58 |
Net Debt/EBITDA |
0.10 | 0.01 | 0.08 | 0.34 | 1.29 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.03 | 0.08 | 0.71 | 0.02 | — |
Operating CF/Net income |
0.28 | 0.56 | 0.76 | 0.67 | 0.00 |
Capex/Depreciation |
0.00 | 0.09 | (0.14) | (11.05) | 0.00 |
Interest Coverage |
(174.23) | (581.90) | (1,418.29) | (306.40) | — |
| (141.66%) | (118.29%) | (1,326.67%) | (669.04%) | 0.00% | |
| (131.23%) | (106.03%) | (896.98%) | (389.53%) | 0.00% | |
ROIC |
(82.19%) | (35.88%) | (16,094.45%) | 0.00% | 0.00% |
Return on Tangible Assets |
(3,134.38%) | 646.28% | (1,278.79%) | (362.30%) | 105.99% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
3,667.00% | 1,282.38% | 1,168.82% | 22,431.46% | 0.00% |
Intangible Assets out of Total Assets |
0.88 | 0.99 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2,350.15% | 341.99% | 209.25% | 6,068.54% | — |
Graham Net Nets |
0.09 | (0.28) | 0.12 | 0.01 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(345.95%) | (200.36%) | (209.37%) | (4.62%) | — |
Free Cash Flow Yield |
(77.62%) | (100.20%) | (149.82%) | (3.12%) | — |
Revenue per Share |
0.05 | 0.31 | 0.68 | 0.01 | 0.00 |
Operating CF per Share |
(0.58) | (2.46) | (6.51) | (1.87) | 0.00 |
Capex per Share |
0.00 | 0.03 | 0.00 | (0.06) | 0.00 |
Free Cash Flow per Share |
(0.58) | (2.42) | (6.52) | (1.93) | 0.00 |
Cash per Share |
0.15 | 0.03 | 0.69 | 0.95 | 0.00 |
Shareholders Equity per Share |
1.51 | 7.05 | 0.72 | 0.85 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.51 | 7.05 | 0.72 | 0.85 | 0.00 |
Free Cash Flow |
(5.85) | (4.80) | (7.00) | (1.39) | 0.00 |
Working Capital |
0.66 | (1.35) | 0.62 | 0.43 | (0.02) |
Capital Expenditures |
— | 0.07 | 0.00 | (0.04) | 0.00 |
Net Current Asset Value |
0.66 | (1.35) | 0.56 | 0.31 | (0.02) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | (0.11) | 0.00 | 4.84 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||
Depreciation/Fixed assets |
1,646.72 | 261.25 | 0.26 | 0.03 | 0.00 |
Cash ROIC |
(35.06%) | (34.27%) | (462.47%) | (107.15%) | 0.00% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.33 | 0.48 | 3.44 | 0.00 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
739.76 | 1,295.84 | 171.31 | 3,000.12 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 22.51 | 0.00 | — |
Average Payables |
0.63 | 0.49 | 0.09 | — | — |
Average Assets |
15.73 | 8.21 | 1.03 | 0.51 | — |
Average Common Equity |
14.57 | 7.36 | 0.69 | 0.30 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026